Breaking News
LAST CHANCE for Cyber Monday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

A Chilean tree holds hope for new vaccines - if supplies last

Stock MarketsOct 06, 2021 09:23PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
5/5 © Reuters. The seeds of a Quillay soapbark tree are seen at the University of California in Berkeley, U.S., August 17, 2021. REUTERS/Nick Otto 2/5

By Aislinn Laing and Allison Martell

CASABLANCA, Chile (Reuters) -Down a dusty farm track in Chilean wine country, behind a wooden gate wrapped in chains, forestry experts are nursing a plantation of saplings whose bark holds the promise of potent vaccines.

Quillay trees, technically known as Quillaja saponaria, are rare evergreens native to Chile that have long been used by the indigenous Mapuche people to make soap and medicine. In recent years, they have also been used to make a highly successful vaccine against shingles and the world’s first malaria vaccine, as well as foaming agents for products in the food, beverage and mining industries.

Now two saponin molecules, made from the bark of branches pruned from older trees in Chile’s forests, are being used for a COVID-19 vaccine developed by drugmaker Novavax (NASDAQ:NVAX) Inc. The chemicals are used to make adjuvant, a substance that boosts the immune system.

Over the next two years, Maryland-based Novavax plans to produce billions of doses of the vaccine, mostly for low- and middle-income countries, which would make it one of the largest COVID-19 vaccine suppliers in the world.

With no reliable data on how many healthy quillay trees are left in Chile, experts and industry officials are divided on how quickly the supply of older trees will be depleted by rising demand. But nearly everyone agrees that industries relying on quillay extracts will at some point need to switch to plantation-grown trees or a lab-grown alternative.

A Reuters analysis of export data from trade data provider ImportGenius shows that the supply of older trees is under increasing pressure. Exports of quillay products more than tripled to more than 3,600 tonnes per year in the decade before the pandemic.

Ricardo San Martin, who developed the pruning and extraction process that created the modern quillay industry, said producers must immediately work toward making quillay products from younger, plantation-grown trees.

“My estimate four years ago was that we were heading towards the sustainability limit,” he said.

San Martin said he has toiled through the COVID-19 pandemic in the basement of his oceanfront cabin in Sea Ranch, California, to refine a process that could help produce saponins from leaves and twigs in order to maximize the yield.

“I am working as though this needs to be done yesterday,” said San Martin, who is also sponsoring a project in which drones would count quillay trees in remote and hard-to-access forests, to determine how many are left.

Quillay producers and their customers say the harvest can continue for now without decimating the supply of older trees.

“We continue to monitor the situation in Chile, in close collaboration with our supplier, but at this time we are confident in our supply,” Novavax said in a statement to Reuters. The company also said it was confident that uses such as “life-saving vaccines will be prioritized.”

The desert-plant extract company Desert King International Ltd, which runs the Casablanca plantation, is Novavax’s sole supplier of quillay extracts and Chile’s largest quillay exporter by far.

The company’s manager in Chile, Andres Gonzalez, told Reuters it is set to produce enough quillay extract from older trees to make up to 4.4 billion vaccine doses in 2022. With new supplies from privately owned native forests, they have enough raw material to meet demand for the rest of this year and part of next, he said.

Gonzalez said the company, where San Martin is a consultant, has built a new production plant and has the capacity to supply other interested pharmaceutical firms - all without harming the forests.

He acknowledged, however, that “at some point these native forests will come to an end.”

“We want to start having very productive plantations, and we are working on that," he said.

A relatively small volume of quillay extract is required to make vaccines - just under one milligram per dose - but the supply is stretched by the demand from other industries. Quillay products are used, for instance, as a natural additive in animal feed, a biopesticide and an agent to reduce pollution in mining.

Individual quillay trees grow outside of Chile, but Chile is the only country where mature quillay is harvested from forests in large quantities.

AN ELUSIVE INGREDIENT

Novavax’s adjuvant, known as Matrix-M, contains two key saponin molecules. One of those, called QS-21, is more difficult to access because it is found mainly in trees that are at least 10 years old.

Among major pharmaceutical companies, only GlaxoSmithKline (NYSE:GSK) PLC and Novavax have bet heavily on QS-21, a relatively new pharmaceutical ingredient.

GSK’s highly successful vaccine against shingles, Shingrix, and several other promising experimental vaccines contain QS-21 supplied by Desert King. In a statement, GSK said it has “no specific challenges relating to sustainable supply” of QS-21.

The quillay-based adjuvant used in Shingrix is also part of the world’s first malaria vaccine, Mosquirix. On Wednesday, the World Health Organization said it should be widely given to African children, marking what could be a major advance against malaria.

No other COVID-19 vaccine manufacturers are relying on quillay bark extracts. Some drugmakers are developing synthetic alternatives, but these could be years from regulatory approval. Switching out the ingredients in any existing vaccine would require new clinical studies to prove the product is safe and effective.

The Massachusetts-based pharmaceutical company Agenus (NASDAQ:AGEN) stopped selling bark-derived QS-21 several years ago to focus full-time on trying to grow it from quillay plant cells in a laboratory.

“The shortage of QS-21 has been an issue for a while,” said Jason Paragas, Agenus vice president of strategic initiatives and growth exploration. “We saw it before COVID, and we made the hard decision that we had to change.”

Paragas said it is too soon to say when an alternative could be ready.

Entrepreneur Gaston Salinas said his Davis, California-based startup Botanical Solution Inc can already produce QS-21 from quillay tissue starting with seeds in the lab, and aims to eventually produce the chemical on a large scale to supply pharmaceutical companies.

“You cannot afford to over-exploit the native Chilean forest because of a desire to develop modern vaccines. You need to find other ways to develop your products, even if it’s something so important, ” he said.

AN EYE TOWARD THE FUTURE

Inside the gate of the carefully guarded Desert King plantation, gardeners carefully tend to the young trees using fertilizers and bountiful supplies of water. They were cloned from full-grown cousins whose dusty gray bark was especially rich in saponins.

If all goes well, the plantation could be producing for one customer in two to three years, according to Desert King’s business development manager Damian Hiley. He declined to name the company.

Desert King has its eye on future vaccines, some already in the works.

In early 2020, for instance, GSK licensed an experimental tuberculosis vaccine that contains GSK’s QS-21-based adjuvant to the Bill and Melinda Gates Medical Research Institute. It showed promising results in a mid-stage trial.

And in April, researchers at Oxford University announced that a new malaria vaccine containing Novavax’s Matrix-M adjuvant appeared to be highly effective in a trial involving 450 children in Burkina Faso.

Gustavo Cruz, a researcher at the University of Chile who worked with San Martin to industrialize production of quillay, said he generally trusts quillay producers to manage supply and demand. He is more worried about other threats - specifically drought and fire.

“The trees do eventually regrow,” he said, “but there comes a time when they don't anymore.”

(Aislinn Laing reported from Casablanca; Allison Martell from Toronto. Additional reporting by Nivedita Balu in Bangalore. Editing by Caroline Humer, Peter Henderson and Julie Marquis)

A Chilean tree holds hope for new vaccines - if supplies last
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Yankee Steve
Yankee Steve Oct 06, 2021 4:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Waiting for this vaccine to be approved for EUA this 4th qtr
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email